Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV Vaccine in 9–26-Year-Old Females (China, Phase III)
CTR20180907Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of qHPV vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical intraepithelial neoplasia grade 2, cervical adenocarcinoma, HPV16 infection (HPV16), sponsored by Merck & Co.. Started Jun 2018; status: active.
02
Drugs
qHPV vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical intraepithelial neoplasia grade 2cervical adenocarcinomaHPV16 infection (HPV16)
Beyond the preview
Go deeper on CTR20180907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180907.